Oxford, UK, March 17, 2009 - Oxford Gene Technology (OGT) is pleased to announce the acquisition of Sense Proteomic Ltd., a UK-based company engaged in the discovery of disease-specific biomarkers based on its innovative functional protein array technology.
Using its proprietary protein array platform, Sense Proteomic has identified autoantibody signatures with the potential to:
• improve disease diagnosis and prognosis
• identify stage of a disease by monitoring the changes in autoantibody production during disease progression
• monitor the response to therapeutic interventions
• improve clinical outcomes by the stratification of patients for clinical trials and treatment.
Sense Proteomic has identified biomarker panels for several diseases including prostate cancer and systemic lupus erythematosus, and has other biomarker discovery programmes in progress.
Mike Evans, OGT’s CEO, said: “Sense Proteomic’s highly skilled scientific team has already demonstrated significant progress in developing biomarker panels based on its novel functional protein array platform. This deal, combined with our recent development of an ultra high throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance.”
Rachel Fallon, Sense Proteomic’s joint CEO, said: “This transaction represents a rare opportunity to discover important biomarkers for disease using more than one approach. The biomarkers can be detected using a simple blood test for early diagnosis and prognosis of disease. We look forward to integrating with OGT’s current capabilities and microarray expertise.”